Literature DB >> 27306888

Do patients with incidentally discovered bilateral adrenal nodules represent an early form of ARMC5-mediated bilateral macronodular hyperplasia?

Holly Emms1,2, Ioanna Tsirou3, Treena Cranston4, Stylianos Tsagarakis3, Ashley B Grossman5.   

Abstract

Bilateral adrenal macronodular hyperplasia (BMAH) is a rare form of Cushing's syndrome characterised by the presence of bilateral secretory adrenal nodules and hypercortisolism. Familial studies support a genetic basis for BMAH, and the disease has been linked to mutations in ARMC5, a gene shown to have a tumour suppressor-like action in the development of adrenal nodules. This study aimed to investigate whether ARMC5 mutations play a role in the development of incidentally discovered bilateral adrenal nodules. We investigated 39 patients with incidentally discovered bilateral adrenal nodules >0.8 cm in diameter who underwent extensive biochemical testing to look for signs of subclinical hypercortisolism. Genomic DNA was analysed by Sanger sequencing, using primers targeted to ARMC5 transcripts. Of the 39 patients included in our study, three were identified as having variants in ARMC5. Two of these are unlikely to be clinically significant, but there is evidence that the third mutation, Chr16:g.31476122;c.1778G>C (p.Arg593Pro), may be pathogenic. Another variant, affecting the same amino-acid residue c.1777C>T (p.Arg593Trp), has been identified previously in two studies of BMAH patients, where it has been shown to segregate with disease in one BMAH family. This patient had biochemical evidence of hypercortisolism in the absence of overt Cushing's syndrome, and underwent bilateral adrenalectomy separated in time. The presence of a probably clinically significant mutation in ARMC5 in one patient with bilateral adrenal incidentalomas adds to the growing body of evidence in support of ARMC5 as a critical mediator of adrenal nodule development. In addition, the absence of significant ARMC5 mutations in 38 of our patients represents an important negative finding, demonstrating the degree of variability within the pathogenesis of adrenal nodule development.

Entities:  

Keywords:  ARMC5; Adrenal hyperplasia; Adrenal incidentalomas; Adrenal nodule; Cushing’s syndrome

Mesh:

Substances:

Year:  2016        PMID: 27306888     DOI: 10.1007/s12020-016-0988-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  17 in total

1.  Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features.

Authors:  R Rossi; L Tauchmanova; A Luciano; M Di Martino; C Battista; L Del Viscovo; V Nuzzo; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

Review 2.  Genetics of adrenal tumors associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias.

Authors:  Constantine A Stratakis; Sosipatros A Boikos
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-11

3.  Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome.

Authors:  A Lacroix; N Ndiaye; J Tremblay; P Hamet
Journal:  Endocr Rev       Date:  2001-02       Impact factor: 19.871

4.  Primary Aldosteronism and ARMC5 Variants.

Authors:  Mihail Zilbermint; Paraskevi Xekouki; Fabio R Faucz; Annabel Berthon; Alexandra Gkourogianni; Marie Helene Schernthaner-Reiter; Maria Batsis; Ninet Sinaii; Martha M Quezado; Maria Merino; Aaron Hodes; Smita B Abraham; Rossella Libé; Guillaume Assié; Stéphanie Espiard; Ludivine Drougat; Bruno Ragazzon; Adam Davis; Samson Y Gebreab; Ryan Neff; Electron Kebebew; Jérôme Bertherat; Maya B Lodish; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2015-03-30       Impact factor: 5.958

5.  Corticotropin-independent macronodular adrenal hyperplasia: a clinicopathologic correlation.

Authors:  J M Swain; C S Grant; R T Schlinkert; G B Thompson; J A vanHeerden; R V Lloyd; W F Young
Journal:  Arch Surg       Date:  1998-05

6.  Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors.

Authors:  D Vezzosi; D Cartier; C Régnier; P Otal; A Bennet; F Parmentier; M Plantavid; A Lacroix; H Lefebvre; P Caron
Journal:  Eur J Endocrinol       Date:  2007-01       Impact factor: 6.664

7.  Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation.

Authors:  Fabio R Faucz; Mihail Zilbermint; Maya B Lodish; Eva Szarek; Giampaolo Trivellin; Ninet Sinaii; Annabel Berthon; Rossella Libé; Guillaume Assié; Stéphanie Espiard; Ludivine Drougat; Bruno Ragazzon; Jerome Bertherat; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2014-03-06       Impact factor: 5.958

8.  ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome.

Authors:  Guillaume Assié; Rossella Libé; Stéphanie Espiard; Marthe Rizk-Rabin; Anne Guimier; Windy Luscap; Olivia Barreau; Lucile Lefèvre; Mathilde Sibony; Laurence Guignat; Stéphanie Rodriguez; Karine Perlemoine; Fernande René-Corail; Franck Letourneur; Bilal Trabulsi; Alix Poussier; Nathalie Chabbert-Buffet; Françoise Borson-Chazot; Lionel Groussin; Xavier Bertagna; Constantine A Stratakis; Bruno Ragazzon; Jérôme Bertherat
Journal:  N Engl J Med       Date:  2013-11-28       Impact factor: 91.245

Review 9.  ACTH-independent macronodular adrenal hyperplasia.

Authors:  André Lacroix
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-04       Impact factor: 4.690

10.  ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions.

Authors:  P Mulatero; F Schiavi; T A Williams; S Monticone; G Barbon; G Opocher; F Fallo
Journal:  J Hum Hypertens       Date:  2015-10-08       Impact factor: 3.012

View more
  5 in total

1.  Mass spectrometry-based steroid profiling in primary bilateral macronodular adrenocortical hyperplasia.

Authors:  Fady Hannah-Shmouni; Annabel Berthon; Fabio R Faucz; Juan Medina Briceno; Andrea Gutierrez Maria; Andrew Demidowich; Mirko Peitzsch; Jimmy Masjkur; Fidéline Bonnet-Serrano; Anna Vaczlavik; Jérôme Bertherat; Martin Reincke; Graeme Eisenhofer; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2020-07       Impact factor: 5.678

2.  ARMC5 Alterations in Primary Macronodular Adrenal Hyperplasia (PMAH) and the Clinical State of Variant Carriers.

Authors:  Chika Kyo; Takeshi Usui; Rieko Kosugi; Mizuki Torii; Takako Yonemoto; Tatsuo Ogawa; Masato Kotani; Naohisa Tamura; Yutaro Yamamoto; Takuyuki Katabami; Isao Kurihara; Kohei Saito; Naotetsu Kanamoto; Hidenori Fukuoka; Norio Wada; Hiroyuki Murabe; Tatsuhide Inoue
Journal:  J Endocr Soc       Date:  2019-07-23

3.  A novel pathogenic variant of ARMC5 in a patient with primary bilateral macronodular adrenal hyperplasia: a case report.

Authors:  Wei Wang; Feng Wei
Journal:  BMC Endocr Disord       Date:  2022-08-22       Impact factor: 3.263

4.  A novel germline ARMC5 mutation in a patient with bilateral macronodular adrenal hyperplasia: a case report.

Authors:  Qiuli Liu; Dali Tong; Jing Xu; Xingxia Yang; Yuting Yi; Dianzheng Zhang; Luofu Wang; Jun Zhang; Yao Zhang; Yaoming Li; Lianpeng Chang; Rongrong Chen; Yanfang Guan; Xin Yi; Jun Jiang
Journal:  BMC Med Genet       Date:  2018-03-27       Impact factor: 2.103

5.  Allelic Variants of ARMC5 in Patients With Adrenal Incidentalomas and in Patients With Cushing's Syndrome Associated With Bilateral Adrenal Nodules.

Authors:  Beatriz Marinho de Paula Mariani; Mirian Yumie Nishi; Ingrid Quevedo Wanichi; Vania Balderrama Brondani; Amanda Meneses Ferreira Lacombe; Helaine Charchar; Maria Adelaide Albergaria Pereira; Victor Srougi; Fabio Yoshiaki Tanno; Filippo Ceccato; Daniela Regazzo; Mattia Barbot; Gianluca Occhi; Nora Maria Elvira Albiger; Marcelo Vieira-Corrêa; Claudio Elias Kater; Carla Scaroni; José Luis Chambô; Maria Claudia Nogueira Zerbini; Berenice B Mendonca; Madson Q Almeida; Maria Candida Barisson Villares Fragoso
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-07       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.